HPR108 Trends in the Prescribing and Dispensing of GLP-1 Anti-Obesity Medications Among U.S. Adults with Cardiovascular Disease and Overweight or Obesity, 2021-2024Duy Do, N. Stucky, Brianna M. Goodwin Cartwright et al.|Value in Health|2025Cited by 0
FDA Cardiovascular Indication Expansion and Dispensing of Semaglutide/Tirzepatide in CVD Patients With Overweight/ObesityDzuy Do, Nicholas L. Stucky, Karthik Murugiah et al.|JACC Advances|2026Cited by 0